The emergence of HIV strains that are resistant to anti-retroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.
References
1.
RichmanD.D.Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Advances in Experimental Medicine & Biology1996; 394: 383–395.
2.
ShirasakaT., KavlickM.F., UenoT., GaoW.Y., KojimaE., AlcaideM.L., ChokekijchaiS., RoyB.M., ArnoldE., & YarchoanR.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences USA1995; 92: 2398–2402.
3.
WintersM.A., CoolleyK.L., ChengP., GirardY.A., HamdanH., KovariL.C., & MeriganT.C.A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation1998; 102: 1769–1775.
4.
MillerV., & LarderB.Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Therapy2001; 6(Suppl. 3): 25–44.
5.
RossL., ScarsellaA., RaffantiS., HenryK., BeckerS., FisherR., LiaoQ., HiraniA., GrahamN., St ClairM., & HernandezJ for the NZT40012 Study Team. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Research & Human Retroviruses2001; 17: 1107–1115.
RousseauM.N., VergneL., MontesB., PeetersM., ReynesJ., DelaporteE., & SegondyM.Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active anti-retroviral therapy. Journal of Acquired Immune Deficiency Syndromes2001; 26: 36–43.
8.
VillalbaN., Gomez-CanoM., HolguinA., & SorianoV.Multiple drug resistance genotype causing failure of anti-retroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues. European Journal of Clinical Microbiology & Infectious Diseases1999; 18: 372–375.
9.
KavlickM.F., WyvillK., YarchoanR., & MitsuyaH.Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. Journal of Infectious Diseases1998; 177: 1506–1513.
10.
de JongJ.J., GoudsmitJ., LukashovV.V., HillebrandM.E., BaanE., HuismansR., DannerS.A., ten VeenJ.H., de WolfF., & JurriaansS.Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS1999; 13: 75–80.
11.
BalottaC., ViolinM., MonnoL., BagnarelliP., RivaC., FacchiG., BerlusconiA., LippiM., RusconiS., ClementiM., GalliM., AngaranoG., & MoroniM.Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. Journal of Acquired Immune Deficiency Syndromes2000; 24: 232–240.
12.
SugiuraW., MatsudaM., MatsudaZ., AbumiH., OkanoA., OishiT., MoriyaK., YamamotoY., FukutakeK., MimayaJ., AjisawaA., TakiM., YamadaK., & NagaiY.Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. Journal of Human Virology1999; 2: 146–153.
13.
BrionesC., & SorianoV.Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain. Antiviral Therapy1999; 4: 125–127.
14.
ClevenberghP., GarraffoR., DurantJ., & DellamonicaP.PharmAdapt: a randomized, controlled, open-label, prospective multi-center study to evaluate the benefit of therapeutic monitoring of protease inhibitors in antiretro-viral experienced HIV-infected patients failing therapy. 12 week results. Aids In Press.
15.
TouloumiG., PaparizosV., SambatakouH., KatsarouO., ChrysosG., KordossisT., AntoniadouA., HatzitheodorouH., StavrianeasN., GargalianosP., KarafoulidouA., LazanasM., GiamarelouH., & HatzakisA.Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals. HIV Clinical Trials2001; 2: 6–16.
16.
ClevenberghP., GarraffoR., DurantJ., DuponM., BaillatV., GastautJ., & DellamonicaP.Long term efficacy of protease inhibitor plasma drug levels monitoring (PI TDM): PharmAdapt W 32 Results.41th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 2001, Chicago, Ill., USA, Abstract 1730.
17.
MillerM.D., MargotN.A., HertogsK., LarderB., & MillerV.Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides, Nucleotides & Nucleic Acids2001; 20.
